Adjuvant Gonadotropin‐releasing hormone analogues for chemotherapy induced premature ovarian failure in premenopausal women
Referencias
Additional references
Ataya M, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone‐releasing hormone agonist for the prevention of chemotherapy‐induced ovarian follicular loss in rats. Cancer Research 1985;45:3651‐6.
Ataya K, Moghissi K. Chemotherapy‐induced premature ovarian failure: mechanisms and prevention. Steroids 1989;54:607‐26.
Ataya K, Ramahi‐Ataya A. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reproductive Toxicology 1993;7:229‐35.
Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone‐releasing hormone agonist inhibits cyclophosphamide‐induced ovarian follicular depletion in rhesus monkeys. Biology of Reproduction 1995;52:365‐72.
Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. A report from the German Hodgkin’s Lymphoma StudyGroup. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen and the use of oral contraceptives during therapy. Journal of Clinical Oncology 2005;23:7555–64.
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 1996;14:1718‐29.
Blumenfeld Z Avivi I Linn S Epelbaum R Ben‐Shahar M Haim N. Prevention of irreversible chemotherapy‐induced ovarian damage in young women with lymphoma by a gonadotrophin‐releasing hormone agonist in parallel to chemotherapy. Human Reproduction 1996;11(8):1620‐6.
Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy‐induced gonadotoxicity in young women. Journal of the Society for Gynecologic Investigation 1999;6:229‐39.
Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:1‐5.
Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. The Oncologist 2007;12:1044‐54.
Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertility and Sterility 2008;89:166‐73.
Blumenfeld Z, von Wolff M. GnRH‐analogues and oral contraceptives for fertility preservation in women during chemotherapy. Human Reproduction Update 2008;14:543‐52.
Bokser L, Szende B, Schally AV. Protective effects of D‐Trp6‐luteinising hormone‐releasing hormone microcapsules against cyclophospamide‐induced gonadotoxicity in female rats. British Journal of Cancer 1990;61:861‐5.
Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, et al. Evidence of castration mediate effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. Journal of Clinical Oncology 1987;5:1771–8.
Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, et al. Early menopause in long‐term survivors of cancer during adolescence. American Journal of Obstetrics and Gynecology 1992;166:788–93.
Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic induced ovarian failure in women with Hodgkin’s disease. I. Hormonal function. JAMA 1979;242:1877–81.
Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964‐1988 in Ontario, Canada. American Journal of Epidemiology 1999;150:245‐54.
Couzinet B, Lahlou N, Thomas G, Thalabard JC, Bouchard P, Roger M, et al. Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and alpha‐subunit in postmenopausal women. Clinical Endocrinology 1991;34:477‐83.
Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin‐releasing hormone antagonists. Fertility and Sterility 2005;83:1333‐8.
Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, et al. Prevention of chemotherapy‐induced menopause by temporary ovarian suppression with goserelin in young early breast cancer patients. Annals of Oncology 2006;17:74‐8.
Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Current Opinion in Obstetrics and Gynecology 2005;17:21‐26.
Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide‐induced testicular damage with an analogue of gonadotropin‐releasing hormone. Lancet 1981;1:1132‐4.
Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine of adjuvant chemotherapy for premenopausal breast cancer patients. Annals of Oncology 1990;1:183–8.
Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. Journal of Clinical Oncology 1999;17:2365–70.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Huser M, Crha I, Ventruba P, Hudecek R, Zakova J, Smardova L, et al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Human Reproduction 2008;23:863‐8.
Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin‐releasing hormone analog from doxorubicin‐induced granulosa cell damage. Gynecologic and Obstetric Investigation 2007;63:102‐6.
Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide‐induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403‐9.
Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy forHodgkin’s disease. Journal of Cancer Research and Clinical Oncology 1987;113:260–6.
Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long‐term survivors of radiation‐ and chemotherapy‐treated childhood cancer. The Journal of Clinical Endocrinology and Metabolism 2003;88(11):5307‐14.
Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Human Reproduction Update 2005;11:69–89.
Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. European Journal of Gynaecological Oncology 2004;25:90‐2.
Matikainen T, Ding YQ, Vergara M, Huhtainiemi I, Couzinet B, Schaison G. Differing responses of plasma bioactive and immunoreactive follicle‐stimulating hormone antagonist and agonist treatments in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1992;75:820‐5.
Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Human Reproduction 1999;14:1903‐7.
Meirow D, Nugent D. The eddects of radiotherapy and chemotherapy on female reproduction. Human Reproduction Update 2001;7:535‐43.
Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide‐induced ovarian follicular destruction in mice. Human Reproduction 2004;19(6):1294‐9.
Moore HC. Following treatment for breast cancer. The incidence of treatment‐related amenorrhea is related to patient age and to the treatment regimen. Current Oncology Reports 2000;2:587‐93.
Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Standord experience. International Journal of Radiation Oncology, Biology, Physics 1990;19:873‐80.
Peng P, Yang DZ, Zheng CY, Mo YQ, He YM, Zhang QX. Effects of gonadotropin releasing hormone analogues on chemotherapy‐induced ovarian function damage in rat. Zhonghua Fu Chan Ke Za Zhi 2007;42:546‐50.
Rabinovici J, Rothman P, Monroe SE, Nerenberg C, Jaffe RB. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin‐releasing hormone antagonist (Ganirelix) with minimal histamine‐releasing properties: studies in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1992;75:1220‐5.
Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, et al. Gonadotropin‐releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514‐23.
Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy‐induced gonadal damage. JAMA 1988;259:2123–5.
Sobrinho LG, Levine RA, DeConti RC. Amenorrhea inpatients with Hodgkin’s disease treated with anti‐neoplastic agents. Amarican Journal of Obstetric and Gynecology 1971;109:135–9.
Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin‐releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis and Rheumatism 2005;52:2761‐7.
Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetric and Gynecology 2003;101:251‐7.
Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for pre‐menopausal women with early breast cancer (EBC). Breast Cancer Research and Treatment 2008;110:411‐6.
Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide‐induced ovarian failure. New England Journal of Medicine 1973;289:1159‐62.
